A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242316982 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Willy Smeralda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Normandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French Ministry of Scientific Research and Innovation, the Region Normandie and the European Union via the European Regional Development Fund (FEDER)., French State (Research Ministry).
Abstract (Originalsprache)
Alzheimer’s disease (AD) is the most widespread form of senile dementia worldwide and represents a leading socioeconomic problem in healthcare. Although it is widely debated, the aggregation of the amyloid β peptide (Aβ) is linked to the onset and progression of this neurodegenerative disease. Molecules capable of interfering with specific steps in the fibrillation process remain of pharmacological interest. To identify such compounds, we have set up a small molecule screening process combining multiple experimental methods (UV and florescence spectrometry, ITC, and ATR-FTIR) to identify and characterise potential modulators of Aβ1-42 fibrillation through the description of the biochemical interactions (molecule–membrane Aβ peptide). Three known modulators, namely bexarotene, Chicago sky blue and indomethacin, have been evaluated through this process, and their modulation mechanism in the presence of a biomembrane has been described. Such a well-adapted physico-chemical approach to drug discovery proves to be an undeniable asset for the rapid characterisation of compounds of therapeutic interest for Alzheimer’s disease. This strategy could be adapted and transposed to search for modulators of other amyloids such as tau protein.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Normandie Université, UNICAEN, CERMN, Boulevard Becquerel, 14000 Caen, France.
- CIMAP, ENSICAEN, UNICAEN, UMR6252 CNRS, CEA, Normandie Université, 6 Bd du Maréchal Juin, 14050 Caen, France.
- Pharmacie à Usage Intérieur, Centre Hospitalier de Vire, Normandie, 14504 Vire, France.
- CBMN, CNRS UMR 5248, Université de Bordeaux, 33600 Pessac, France.
ORCID-Profile: Willy Smeralda, Marc Since, Dimitri Fayolle, Julien Cardin, Aurélie Malzert-Freon
Förderung
- French Ministry of Scientific Research and Innovation
- the Region Normandie and the European Union via the European Regional Development Fund (FEDER).
- French State (Research Ministry)
- Region Normandie and the European Union via the European Regional Development Fund (FEDER)
Zitieren
APA
Smeralda, W., Since, M., Corvaisier, S., Fayolle, D., Cardin, J., Duprey, S., Jourdan, J. P., Cullin, C., & Malzert-Freon, A. (2023). A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316982
Vancouver
Smeralda W, Since M, Corvaisier S, Fayolle D, Cardin J, Duprey S, et al. A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242316982
BibTeX
@article{Smeralda2023,
author = {Smeralda, Willy and Since, Marc and Corvaisier, Sophie and Fayolle, Dimitri and Cardin, Julien and Duprey, Sylvain and Jourdan, Jean-Pierre and Cullin, Christophe and Malzert-Freon, Aurélie},
title = {A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242316982}
}
EUVIMED